.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Chinese Patent Office
US Army
Dow
Daiichi Sankyo
Teva
UBS
McKesson
Mallinckrodt
Harvard Business School

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204150

« Back to Dashboard

NDA 204150 describes DESVENLAFAXINE, which is a drug marketed by Alembic Pharms Ltd, Sun Pharma Global, Teva Pharms Usa, Actavis Labs Fl, Lupin Ltd, Mylan Pharms Inc, Sandoz Inc, West-ward Pharms Int, and Zydus Pharms Usa Inc, and is included in eleven NDAs. It is available from one supplier. Additional details are available on the DESVENLAFAXINE profile page.

The generic ingredient in DESVENLAFAXINE is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.

Summary for 204150

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Formulation / Manufacturing:see details

Medical Subject Heading (MeSH) Categories for 204150

Suppliers and Packaging for NDA: 204150

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DESVENLAFAXINE desvenlafaxine TABLET, EXTENDED RELEASE;ORAL 204150 NDA Sun Pharmaceutical Industries, Inc. 63304-191 63304-191-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (63304-191-30)
DESVENLAFAXINE desvenlafaxine TABLET, EXTENDED RELEASE;ORAL 204150 NDA Sun Pharmaceutical Industries, Inc. 63304-191 63304-191-90 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (63304-191-90)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength50MG
Approval Date:Mar 4, 2013TE:BCRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength100MG
Approval Date:Mar 4, 2013TE:BCRLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
McKesson
US Army
Daiichi Sankyo
Fish and Richardson
Dow
Deloitte
Julphar
Johnson and Johnson
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot